UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): March 20, 2023

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada	**001-36019**	**26-1434750**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

26 Main Street, Chatham, New Jersey 07928
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the "Company") updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.01 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit No.	**Description.**
99.01	Corporate Presentation by the Company for March 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

Date: March 20, 2023

By: /s/ Bradley Saenger
Bradley Saenger
Chief Financial Officer

Exhibit 99.01

Cautionary Note on Forward-Looking Statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the "SEC") on March 13, 2023, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Who We Are

OUR MISSION

Tonix Pharmaceuticals is committed to improving population health by **inventing and developing** innovative therapies and vaccines, through **broad in-house capabilities and creative collaborations**, to help address important unmet needs.

OUR VISION

Tonix strives to be a leader in providing **novel drug therapies and vaccines** to **improve population health around the world.**

Investment Highlights

DIVERSE PIPELINE

Tonix's core focus is on **central nervous system** disorders, but we also target unmet needs across multiple therapeutic areas including **immunology, infectious disease** and **rare disease.**

IN-HOUSE CAPABILITIES

Investment in domestic**, in-house, R&D and manufacturing** to accelerate development timelines and improve the ability to respond to pandemics.

STRATEGIC PARTNERSHIPS

Partnering strategically with other **biotech companies**, **world-class academic and non-profit research organizations** to bring innovative therapeutics to market faster.

FINANCIAL POSITION

Tonix had approximately **$120 M in cash and cash equivalents** as of 12/31/22. Tonix has no debt.

Pipeline: Key Programs

Candidates*	Indication	Status/Next Milestone
TNX-102 SL[1]	Fibromyalgia (FM) Long COVID (PASC[2])	Mid-Phase 3 - >50% enrolled Phase 2 - enrolling
TNX-1300[3]	Cocaine Intoxication - *FDA Breakthrough Designation*	Mid-Phase 2, Targeted 2Q 2023 Start
TNX-1900[4]	Prevention of Chronic Migraine	Phase 2 – enrolling[5]
TNX-601 ER	Depression	Phase 2 - enrolling[6]
TNX-1600[7]	Depression, PTSD and ADHD	Preclinical
TNX-2900[8]	Prader-Willi Syndrome - *FDA Orphan Drug Designation*	Phase 2 ready
TNX-1500[9]	Organ Transplant Rejection/ Autoimmune Conditions	Phase 1, Targeted 2Q 2023 Start
TNX-1700[10]	Gastric and colorectal cancers	Preclinical
TNX-801[11]	Smallpox and mpox vaccine	Phase 1, Targeted 2H 2023 Start
TNX-1850[12]	COVID-19 Vaccine (horsepox-based live virus vaccine)	Preclinical
TNX-2300[13]	COVID-19 Vaccine	Preclinical
TNX-3600[14]	COVID-19 Therapeutic Platform (fully human monoclonal antibodies)	Preclinical
TNX-3700[15]	COVID-19 Vaccine (zinc nanoparticle mRNA technology)	Preclinical

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication.
[1]TNX-102 SL (cyclobenzaprine HCl sublingual tablets) also has active INDs for Agitation in Alzheimer's Disease (AAD), Alcohol Use Disorder (AUD), and Posttraumatic Stress Disorder (PTSD). All indications are Phase 2 ready.
[2]Post-Acute Sequelae of COVID-19.
[3]TNX-1300 (double-mutant cocaine esterase) was licensed from Columbia University.
[4]Acquired from Trigemina; license agreement with Stanford University. Planned investigator initiated Binge Eating Disorder (BED) study is expected start 2Q 2023.
[5]A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900.
[6]Phase 1 trial for formulation development was completed outside of the U.S.; Other potential indications include PTSD and neurocognitive dysfunction from steroids
[7]Acquired from TRimaran Pharma; license agreement with Wayne State University
[8]Co-exclusive license agreement with French National Institute of Health and Medical Research (Inserm)
[9]anti-CD40L humanized monoclonal antibody
[10]Recombinant trefoil factor 2 (rTFF2) based protein; licensed from Columbia University
[11]Live attenuated vaccine based on horsepox virus
[12]Live attenuated vaccine based on horsepox virus vector, expressed SARS-CoV-2 spike protein. TNX-1850 is based on the BA.2 variant spike protein.
[13]Live attenuated vaccine based on bovine parainfluenza (BPI) virus
[14]Fully human monoclonal antibody generated from COVID-19 convalescent patients
[15]COVID vaccine based on mRNA in zinc nanoparticle (ZNP) formulation with CD40L molecular trigger

TONIX PHARMACEUTICALS

Five Late-Stage CNS Programs to be in the Clinic by 1H 2023
Three Studies Enrolling Now

CNS PORTFOLIO

ENROLLING

- **In Phase 3:**
  - TNX-102 SL for fibromyalgia (>50% enrolled) — Potential Pivotal Study
- **In Phase 2:**
  - TNX-102 SL for fibromyalgia-type Long COVID — Potential Pivotal Study
  - TNX-1900 for migraine headache (new mechanism for US patients) — Potential Pivotal Study
  - TNX-601 ER for major depressive disorder (new mechanism for US patients) — Potential Pivotal Study

ENTERING PHASE 2

- **In 2Q 2023:**
  - TNX-1300 for cocaine intoxication (FDA Breakthrough Therapy Designation) — Potential Pivotal Study

[1]Not approved for any indication

TONIX PHARMACEUTICALS

TNX-102 SL*
Cyclobenzaprine (Protectic®) Pipeline in a Product

A unique, sublingual formulation of cyclobenzaprine designed to optimize delivery and absorption

Potent binding and antagonist activities at the serotonin-5-HT2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors to facilitate restorative sleep

Innovative and proprietary PROTECTIC® Rapid drug exposure following nighttime administration

Differentiators:

Relative to Oral Cyclobenzaprine
- Lower daytime exposure
- Avoids first-pass metabolism
- Reduces risk of pharmacological interference from major metabolite

Relative to Standard of Care
- Potential for better tolerability while maintaining efficacy

Patents Issued

*TNX-102 SL has not been approved for any indication.

Fibromyalgia
Status: Mid-Phase 3
- One positive Phase 3 study (RELIEF) completed
- Second Phase 3 study (RALLY) missed primary endpoint
- Confirmatory Phase 3 study (RESILIENT) is currently enrolling
  - >50% enrolled

Next Steps: Interim analysis results expected 2Q 2023

Long COVID
Status: Phase 2
- Phase 2 study (PREVAIL) is currently enrolling

Next Steps: Trial enrollment is in process

TONIX PHARMACEUTICALS

TNX-102 SL*: Fibromyalgia
Cyclobenzaprine Protectic® Sublingual Tablets

CNS PORTFOLIO

PROFILE

Fibromyalgia (FM) is a chronic pain disorder resulting from amplified sensory and pain signaling within the CNS

- Afflicts an estimated 6-12 million adults in the U.S., approximately 90% of whom are women[1]
- Symptoms include chronic widespread pain, nonrestorative sleep, fatigue, and cognitive dysfunction
- Patients struggle with daily activities, have impaired quality of life, and frequently are disabled
- Physicians and patients report common dissatisfaction with currently marketed products

When the check engine light malfunctions, the light is on even though the car is not malfunctioning

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Fibromyalgia

Additional Indications: Long COVID, PTSD, Agitation in Alzheimer's, Alcohol Use Disorder

Status: One Positive Phase 3 study RELIEF completed

Second Phase 3 study RALLY missed primary endpoint

Confirmatory Phase 3 study RESILIENT is currently enrolling

Next Steps: Interim analysis results expected 2Q 2023

*TNX-102 SL has not been approved for any indication.

[1]American Chronic Pain Association (www.theacpa.org, 2019)

TONIX PHARMACEUTICALS

TNX-102 SL: Phase 3 RESILIENT Study Design

CNS PORTFOLIO

General study characteristics:

- Randomized, double-blind, placebo-controlled study in fibromyalgia
- U.S. sites only, expected to enroll approximately 470 patients
- One unblinded interim analysis based on 50% of randomized participants

Primary Endpoint:

- Daily diary pain severity score change from baseline to Week 14 (TNX-102 SL vs. placebo)
  - Weekly averages of the daily numerical rating scale scores
  - Analyzed by mixed model repeated measures with multiple imputation (MMRM with MI)

TNX-102 SL once-daily at bedtime
5.6 mg (2 x 2.8 mg tablets)*

Placebo once-daily at bedtime

14 weeks

*Two week run in at 2.8 mg dose at bedtime, followed by 12 weeks at 5.6 mg dose

ClinicalTrials.gov Identifier: NCT05273749
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

TONIX PHARMACEUTICALS

Fibromyalgia-Type Long COVID

- Long COVID is a heterogeneous condition that displays elements of nociplastic pain in many individuals, who experience otherwise unexplained symptoms[1-2]



Symptoms (multi-site pain, fatigue, sleep disorders and cognitive dysfunction) overlap with the key symptoms of fibromyalgia

Nociceptive pain[3]: (*new term for "Central Sensitization)* Pain due to the activation of nociceptors that arises from actual or threatened damage to non-neural tissue

[1]Bierle DM, et al. Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome. J Prim Care Community Health 2021;12:21501327211030826. doi: 10.1177/21501327211030826.
[2]Moghimi, N. et al. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection Curr Neurol Neurosci Rep. 2021;21(9):44. doi: 10.1007/s11910-021-01130-1.
[3]Trouvin AP, et al. *Best Pract Res Clin Rheumatol.* 2019;33(3):101415.

TONIX PHARMACEUTICALS

TNX-102 SL*: Fibromyalgia-Type Long COVID (PASC)
Cyclobenzaprine Protectic® Sublingual Tablets

PROFILE

- Occurs in approximately 13% of recovered COVID-19 patients[1]
- As many as 40% of Long COVID patients experience multi-site pain, a hallmark of fibromyalgia[2,3]
- Symptoms of Long COVID, like multi-site pain, fatigue and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- In August 2022, the HHS released the National Research Action Plan on Long COVID[4] which endorses the connection between Long COVID and chronic fatigue syndrome

DEVELOPMENT PROGRAM

Market Entry: Fibromyalgia-Type Long COVID (PASC)

Additional Indications: Fibromyalgia, PTSD, Agitation in Alzheimer's, Alcohol Use Disorder

Status: Phase 2 study PREVAIL is currently enrolling

Next Steps: PREVAIL trial enrollment is in process

Patents Issued

*TNX-102 SL has not been approved for any indication.

[1]September 1, 2022- CDC - https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
[2]Harris, H, et al. Tonix data on file. 2022
[3]TriNetX Analytics
[4]Department of Health and Human Services, Office of the Assistant Secretary for Health. 2022. National Research Action Plan on Long COVID. 200 Independence Ave SW, Washington, DC 20201.

TONIX PHARMACEUTICALS

TNX-102 SL: Phase 2 PREVAIL Study Design

Study characteristics:

- Randomized, double-blind, placebo-controlled study of TNX-102 SL in fibromyalgia-type Long COVID
- U.S. sites only, expected to enroll approximately 470 patients
- One unblinded interim analysis based on 50% of randomized participants

Primary Endpoint:

- Daily diary pain severity score change from baseline to Week 14 (TNX-102 SL vs. placebo)
  - Weekly averages of the daily numerical rating scale scores
  - Analyzed by mixed model repeated measures with multiple imputation (MMRM with MI)

*Two week run in at 2.8 mg dose at bedtime, followed by 12 weeks at 5.6 mg dose

ClinicalTrials.gov Identifier: NCT05472090
"A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)"

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-601 ER*: Depression
Tianeptine Hemioxalate Extended-Release Tablets (39.4 mg)

PROFILE

- A novel, oral, extended-release once-daily tablet
- Treatment effect of tianeptine sodium immediate release *t.i.d.* in depression is well-established
- Tianeptine restores neuroplasticity in animal models
- Indirectly modulates the glutamatergic system
- Does not interact with AMPA, NMDA or Kainate receptors[1]

Differentiators:

Relative to tianeptine IR available ex-US:

- Once daily dosing

Relative to traditional antidepressants:

- Unique mechanism of action – beyond neurotransmitter modulation
- Tianeptine sodium IR has similar efficacy but fewer side effects than traditional antidepressants

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Major Depressive Disorder

Additional Indications: PTSD, Neurocognitive Disorder From Corticosteroids

Status: Phase 2 study UPLIFT is currently enrolling

Next Steps: Interim analysis results on first 50% of sample expected 4Q 2023

*TNX-601 ER has not been approved for any indication.

[1]AMPA=α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA=N-methyl-D-aspartate

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-601 ER: Phase 2 UPLIFT Study Design

General study characteristics:

- Randomized, double-blind, placebo-controlled study in Major Depressive Disorder
- Parallel design with two arms – treatment with tianeptine hemioxalate 39.4 mg or placebo
- ~30 U.S. sites only, expected to enroll approximately 300 patients
- One unblinded interim analysis based on 50% of randomized participants expected 4Q'23

Primary Endpoint:

- Mean change from baseline in the Montgomery Åsberg Depression Rating Scale total score at Week 6



ClinicalTrials.gov Identifier: NCT05686408
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) (UPLIFT)

Abbreviations: ER, extended-release; F/U, follow-up; MDE, major depressive episode; N, number

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-1900*: Migraine
Intranasal Potentiated Oxytocin (OT) with Magnesium

PROFILE

- Intranasal OT has potential utility in treating migraine[1]
- Magnesium is known to potentiate the binding of OT to its receptor[2,3]
- One billion individuals worldwide suffer from migraines

Differentiator: Novel non-CGRP antagonist approach to treatment



Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Chronic Migraine

Additional Indications: Acute Migraine, Craniofacial Pain, Insulin Resistance, Binge Eating Disorder

Status: Phase 2 study PREVENTION is currently enrolling[4]

Next Steps: Interim analysis results expected 4Q 2023

Investigator initiated Phase 2 trial in obesity-associated binge eating disorder 2Q 2023

*TNX-1900 has not been approved for any indication. CGRP = calcitonin gene-related peptide.

[1]Tzabazis A, et al. Oxytocin and Migraine Headache. Headache. 2017 May;57 Suppl 2:64-75. doi: 10.1111/head.13082. PMID: 28485846.
[2]Antoni FA, Chadio SE. Essential role of magnesium in oxytocin-receptor affinity and ligand specificity. Biochem J. 1989 Jan 15;257(2):611-4. doi: 10.1042/bj2570611. PMID: 2539090; PMCID: PMC1135623.
[3]Meyerowitz, J.G., *et al.* The oxytocin signaling complex reveals a molecular switch for cation dependence. *Nat Struct Mol Biol* (2022). (https://doi.org/10.1038/s41594-022-00728-4)
[4]A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-1900: Phase 2 PREVENTION Study Design

General study characteristics:

- Randomized, double-blind, placebo-controlled study (three arms– two treatment regimens and one placebo) in chronic migraine
- U.S. sites only, expected to enroll approximately 300 patients
- One unblinded interim analysis based on 50% of randomized participants expected 4Q'23

Primary Endpoint:

- Mean change in the number of migraine headache days between the 28-day Run-In phase and the last 28-days of the Treatment phase (TNX-1900 vs. placebo)



ClinicalTrials.gov Identifier: NCT05679908
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (PREVENTION)

TNX-1300*: Cocaine Intoxication
Cocaine Esterase (CocE)

PROFILE

Cocaine is the main cause for drug-related ED visits[1]

CocE is a recombinant protein that degrades cocaine in the bloodstream

- Rapidly reverses physiologic effects of cocaine
- Drops plasma exposure by 90% in 2 minutes

Differentiators: Rapidly metabolizes cocaine in the bloodstream; no other product currently on the market for this indication

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Cocaine Intoxication

Status: Mid-Phase 2

Next Steps: Initiate new Phase 2 trial 2Q 2023 pending FDA agreement

- Single-blind, placebo (+ usual care) controlled, randomized, potentially pivotal study
- Expected to enroll approximately 60 emergency department patients at sites in the US

FDA Breakthrough Therapy Designation

Awarded Cooperative Agreement Grant from National Institute on Drug Abuse (NIDA)

[1]Havakuk O et al. *J Am Coll Cardiol.* 2017;70:101-113.
ED = emergency department.

 *TNX-1300 has not been approved for any indication.

TNX-2900*: Hyperphagia in Prader-Willi Syndrome
Intranasal Potentiated Oxytocin (OT) with Magnesium

PROFILE

Prader-Willi Syndrome is the most common genetic cause of life-threatening childhood obesity

- Rare disease occurring in 1 in 10,000 to 1 in 30,000 births

Differentiator: No approved therapeutic currently on the market for hyperphagia in PWS

Dangers of PWS Hyperphagia:

Unhealthy behaviors around food[1-4] → Consequences such as obesity, type 2 diabetes, cardiovascular disease[1-5] → Caretaker Burden[1-4]:

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Hyperphagia in Prader-Willi Syndrome

Additional Indications: Rare Hyperphagia Conditions

Status: Phase 2 ready

Next Steps: IND submission

*TNX-2900 is in the pre-IND stage of development and has not been approved for any indication.

RARE DISEASE PORTFOLIO

[1]Miller JL, et al. *Am J Med Genet A.* 2011;155A(5):1040-1049.
[2]Butler MG, et al. *Genet Med.* 2017;19(6):635-642.
[3]Butler MG. NORD. Updated 2018. Accessed May 25, 2022. https://rarediseases.org/rare-diseases/prader-willi-syndrome/
[4]Prader-Willi Syndrome Association USA. Accessed May 25, 2022. https://www.pwsausa.org/what-is-prader-willi-syndrome/
[5]Muscogiuri G, et al. *J Endocrinol Invest.* 2021;44(10):2057-2070.

TONIX PHARMACEUTICALS

TNX-1500*

Next Generation α-CD40 Ligand (CD40L) Antibody

The CD40-CD40L pathway is a pivotal immune system modulator and a well-established and promising treatment target

Differentiators: Expected to deliver efficacy without compromising safety

- **First Generation:** Development halted due to thromboembolic (TE) complications—blood clots—traced to Fc gamma receptor (FcγR)
- **Second Generation:** Eliminated the FcγR TE complication but potency and half life was reduced, limiting utility
- **Third Generation (TNX-1500):** Re-engineered to better modulate the binding of FcγR.

*TNX-1500 is in the pre-IND stage of development and has not been approved for any indication. Patents filed.

Prevention of Allograft Rejection

Status: Phase 1 ready

- Collaborations ongoing with Mass General Hospital on heart and kidney transplantation in non-human primates

Next Steps: Initiate Phase 1 study 2Q 2023

Autoimmune Diseases

Status: Potential future indications include:

Sjögren's Syndrome, Systemic Lupus Erythematosus

- These indications require large studies, but represent large target markets



Contains the full ruplizumab Fab and the engineered Fc region that modulates FcγR-binding, while preserving FcRn function.

TONIX PHARMACEUTICALS

Third-Generation α-CD40L
Engineered to Decrease Risk of Thrombosis

IMMUNOLOGY PORTFOLIO

First-generation anti-CD40L mAbs



Ruplizumab

Constant fragment (Fc) domain interacted with FcγRIIA (CD32A), which suggested a mechanism for the increased risk of thrombosis.[1,2]

Second-generation anti-CD40L proteins



Aglycosyl Ruplizumab | *Dapirolizumab* | *Letolizumab* | *Dazodalibep*

Second-generation anti-CD40L proteins exhibited dramatically reduced binding to FcγRIIA[3-6] but had other issues, including decreased efficacy, shortened half-life, or engendering of anti-drug antibodies (ADAs).[7-9]

Third-generation anti-CD40L mAbs*



TNX-1500

TNX-1500 is engineered to target CD40L therapeutically while reducing FcγRIIA binding and thereby lowering the potential for thrombosis.[1-9]

*Sanofi's frexalimab (formerly SAR441344) and Eledon's tegoprubart (formerly AT-1501) also are Fc modified

[1]Imwald DP, et al. *Circ Res*. 2003;92(9):1041-1048.
[2]Robles-Carrillo L, et al. *J Immunol*. 2010;185(3):1577-1583.
[3]Shock A, et al. *Arthritis Res Ther*. 2015;17(1):234.
[4]Xie JH, et al. *J Immunol*. 2014;192(9):4083-4092.
[5]Ferrant JL, et al. *Int Immunol*. 2004;16(11):1583-1594.
[6]Karnell JL, et al. *Sci Transl Med*. 2019;11(489):eaar6584.
[7]ClinicalTrials.gov identifier: NCT02273960. Updated July 16, 2019. Accessed June 1, 2021. https://clinicaltrials.gov/ct2/show/results/NCT02273960?view=results
[8]Waters J, *Biocentury*; October 26, (2018).
[9]Company data.

TONIX PHARMACEUTICALS

Other anti-CD40L Monoclonal Antibodies in Development

IMMUNOLOGY PORTFOLIO

UCB (Co-developed with Biogen) – Systemic Lupus Erythematosus (SLE)
- Phase 3 Trial Currently Enrolling (NCT04294667)
  - Topline results expected 1H 2024[1]
- Dapirolizumab pegol (pegylated Fab)

Horizon (Agreed to be acquired by Amgen) – Sjögren's Syndrome (SjS)
- Two Positive Phase 2 studies reported[2,3]
- Dazodalibep (tn03 fusion protein)

Sanofi – Sjögren's Syndrome (SjS), Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE)
- Phase 2 Trial Currently Enrolling in SjS (NCT04572841) and SLE (NCT05039840)
- Active Phase 2 Trial in Relapsing MS (NCT04879628)
- SAR441344 (Fc-modified)

Eledon – Amyotrophic Lateral Sclerosis (ALS) and Kidney Transplant
- Phase 2 Trial Completed in ALS (NCT04322149)
- Phase 1/2 Trial Currently Enrolling in Kidney Transplant (NCT05027906)
- Tegoprubart, f.k.a. AT-1501 (Fc-modified)

Lundbeck and AprilBio – Neurology
- Phase 1 Trial Currently Enrolling in Healthy Adults (NCT05136053)
- APB-A1 or Lu AG22515 (HAS fusion protein)

[1]https://www.ucb.com/our-science/pipeline
[2]https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-phase-2-trial-evaluating
[3]https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-phase-2-trial-evaluating-0

TONIX PHARMACEUTICALS

TNX-1700*: Gastric and Colorectal Cancers
Recombinant Trefoil Factor 2 (rTFF2-HSA) Fusion Protein

IMMUNOLOGY PORTFOLIO

Potential New Cancer Treatment

- TNX-1700 (rTFF2) has effects on cancer by altering the tumor micro-environment
- Mechanism of action: suppresses myeloid-derived suppressor cells and activates anti-cancer CD8+ T cells
- Potential synergy with anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs)

Preclinical Evidence for Inhibiting Growth of Cancer Cells

- Data showed that mTFF2-CTP augmented the efficacy of mAb anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP showed greater anti-tumor activity in PD-L1-overexpressing mice
- mTNX-1700 (mTFF2-MSA fusion protein) and anti-PD-1 monotherapy each was able to evoke anti-tumor immunity in the MC38 model of colorectal cancer[1]
- mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in both the MC38 and the CT26.wt models[1]

Patents Filed

Market Entry: Immuno-oncology, combination therapy with PD1 blockers for gastric and colorectal cancer

Status: Preclinical

Next Steps: Animal studies ongoing

Differentiator: No product yet identified consistently augments PD1 effects on cold tumors

Licensed from Columbia University

- Developing in partnership under sponsored research agreement

*TNX-1700 is in the pre-IND stage of development and has not been approved for any indication.

[1]Daugherty, B. et al. March 6, 2023 Keystone Poster; www.tonixpharma.com/wp-content/uploads/2023/03/mTFF2-MSA_mTNX-1700_Suppresses-Tumor-Growth-and-Increases-Survival-in-an-Anti-PD-1-Treated-MC38-Colorectal-Cancer-Model-by-Targeting-MDSCs.pdf

TONIX PHARMACEUTICALS

TNX-801 & TNX-1850*

Recombinant Pox Vaccine (RPV) Platform Using Live Virus Technology

Differentiators:

- **Live virus vaccines are the most established vaccine technology**
  - Starting with Edward Jenner's smallpox vaccine, the first vaccine, which eradicated smallpox
  - Prevents forward transmission
  - Effective in eliciting durable or long-term immunity
- **Economical to manufacture at scale**
  - Low dose because replication amplifies dose in vivo
  - Single shot administration
- **Standard refrigeration required for shipping and storage**

*TNX-801 and TNX-1800/TNX-1850 are in the pre-IND stage of development and has not been approved for any indication. Patents filed.

[1]Noyce RS, et al. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018 Jan 19;13(1):e0188453.
[2]Brennan, Z. Endpoints March 2, 2022 (https://endpts.com/weaker-omicron-variant-is-great-news-for-the-world-but-bad-news-for-covid-related-clinical-trials/)

Mpox and Smallpox Vaccine

Status: Preclinical

- TNX-801 is a cloned version of horsepox[1] (without any insert) purified from cell culture

Next Steps: Developing GMP manufacturing; Initiate Phase 1 Trial 2H 2023

COVID-19 Vaccine

Status: Preclinical

- First version TNX-1800 encodes spike protein from SARS-CoV-2, Wuhan strain
- Planned new version TNX-1850 encode spike protein from SARS-CoV-2 BA.2 strain[2]

Next Steps: Developing TNX-1850 (BA.2) version

TNX-801*
scHPXV (Horsepox)
212,811 bp



TNX-1800*
rHPXV/SARS-CoV-2 S
210,963 bp

TONIX PHARMACEUTICALS

TNX-3600*: COVID-19 Therapeutic/Preventative
Fully Human Monoclonal Antibody

INFECTIOUS DISEASE PORTFOLIO

PROFILE

- Fully human monoclonal antibodies
- Generated from SARS-CoV-2+ asymptomatic individuals or COVID-19 convalescent patients
- Potential to be scaled up quickly and combined with other monoclonal antibodies
- Collaboration with Columbia University



Patents Filed

DEVELOPMENT PROGRAM

Market Entry: COVID-19 treatment and prophylaxis in immuno-compromised individuals

Status: Preclinical

Next Steps: Study inhibition of SARS CoV-2 variants in tissue culture; initiate animal studies in 1H 2023

Differentiators: Potential to decrease response time to newly identified COVID-19 variants, relative to generating murine mAbs followed by humanization

*TNX-3600 is in the pre-IND stage of development and has not been approved for any indication.

[1]Lu R-M, Hwang Y-C, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z
[2]TNX-3600 and TNX-3800 are the designations for a series of monoclonal antibodies; each is in the pre-IND stage of development and has not been approved for any indication.

TONIX PHARMACEUTICALS

Additional Infectious Disease Therapeutics in Development

TNX-2300*: Live Virus Vaccine Based on Bovine Parainfluenza (BPI) Virus

Market Entry: COVID-19 Vaccine
Status: Preclinical
Next Steps: Animal studies with Kansas State University (KSU) to test the effect of co-expression of CD40-ligand to stimulate T cell immunity

TNX-3700*: Zinc Nanoparticle (ZNP) Formulation for mRNA Vaccines

Market Entry: Booster for COVID-19 Vaccines
Status: Preclinical
Next Steps: Research at KSU on CoV-2 spike based vaccine in tissue culture and animals; initiate animal studies in 1H 2023

*TNX-2300 and TNX-3700 are in the pre-IND stage of development and have not been approved for any indication.

Live Virus Vaccine Platform: Recombinant Pox Vaccine (RPV) Technology for Emerging Infectious Diseases and Oncolytics



RPV VECTOR BELIEVED SIMILAR TO EDWARD JENNER'S VACCINE[1-3]

Using Proven Science To Address Challenging Disease States, We Have Created A Programmable Technology Platform Aimed At Combating Future Threats To Public Health

[1]Shrick, L. N Engl J Med 2017; 377:1481-1492. DOI: 10.1056/NEJMc1707600
[2]Esparza, J. Vaccine. 2020 Jun 19; 38(30): 4773–4779. doi: 10.1016/j.vaccine.2020.05.037
[3]Brinkmann, A. Genome Biol. 2020; 21: 286. doi: 10.1186/s13059-020-02202-0

Internal Development & Manufacturing Capabilities

R&D Center (RDC) – Frederick, MD

- **Functions:**
  - Accelerated development of vaccines and antiviral drugs against COVID-19, its variants and other infectious diseases
  - Research advancing CNS and immunology drugs
- **Description:** ~48,000 square feet, BSL-2 with some areas designated BSL-3
- **Status:** Operational

Advanced Development Center (ADC) – North Dartmouth, MA

- **Function:** Development and clinical scale manufacturing of biologics
- **Description:** ~45,000 square feet, BSL-2
- **Status:** Operational

Commercial Manufacturing Center (CMC) – Hamilton, MT

- **Function**: Phase 3 and Commercial scale manufacturing of biologics
- **Description:** ~44-acre green field site, planned BSL-2
- **Status:** Planning for site enabling work in 2023

Architectural Rendering

INFECTIOUS DISEASE PORTFOLIO

TONIX PHARMACEUTICALS

Management Team

Seth Lederman, MD
Co-Founder, CEO & Chairman

Gregory Sullivan, MD
Chief Medical Officer

Bradley Saenger, CPA
Chief Financial Officer

Jessica Morris
Chief Operating Officer

Milestones: Recently Completed and Upcoming

- ☑ 2nd Quarter 2022 Phase 3 RESILIENT study start of TNX-102 SL for the management of fibromyalgia
- ☑ 3rd Quarter 2022 Phase 2 PREVAIL study start of TNX-102 SL for the treatment of Long COVID
- ☑ 1st Quarter 2023 Phase 2 study start of TNX-1900 for the treatment of migraine
- ☑ 1st Quarter 2023 Phase 2 UPLIFT study start of TNX-601 ER for major depressive disorder

Expected Data

- ☐ 2nd Quarter 2023 Interim Analysis results of Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia
- ☐ 4th Quarter 2023 Interim Analysis results of Phase 2 PREVENTION study of TNX-1900 for chronic migraine
- ☐ 4th Quarter 2023 Interim Analysis results of Phase 2 UPLIFT study of TNX-601 ER for major depressive disorder
- ☐ 4th Quarter 2023 topline results of Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia

Expected Clinical Trial Initiations

- ☐ 2nd Quarter 2023 Phase 1 study start of TNX-1500 for prevention of allograft rejection
- ☐ 2nd Quarter 2023 Phase 2 study start of TNX-1300 for the treatment of cocaine intoxication
- ☐ 2nd Half 2023 Phase 1 study start of TNX-801 for prevention of mpox and smallpox


THANK YOU
© 2023 Tonix Pharmaceuticals Holding Corp.